-
Abbott Takes Action On FDA Warning Letter
Thursday, April 13, 2017 - 10:53am | 394Read More...In response to a Wednesday letter by the U.S. Food and Drug Administration, which highlighted numerous regulatory violations on the part of Abbott Laboratories (NYSE: ABT), Abbott told Benzinga that “patient safety comes first” and the firm prioritizes compliance with regulatory...
